Antiviral effects of selected nucleoside analogues against human parechoviruses A1 and A3.
暂无分享,去创建一个
[1] J. Tang,et al. Comparing the Clinical Severity of Disease Caused by Enteroviruses and Human Parechoviruses in Neonates and Infants , 2019, The Pediatric infectious disease journal.
[2] B. McMullan,et al. High prevalence of developmental concern amongst infants at 12 months following hospitalised parechovirus infection , 2018, Journal of paediatrics and child health.
[3] L. Jennings,et al. Human Parechovirus: an Increasingly Recognized Cause of Sepsis-Like Illness in Young Infants , 2017, Clinical Microbiology Reviews.
[4] A. Saitoh,et al. Human parechovirus type 3 infection: An emerging infection in neonates and young infants. , 2017, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.
[5] P. Stockley,et al. Genomic RNA folding mediates assembly of human parechovirus , 2017, Nature communications.
[6] J. Rossen,et al. Enterovirus and parechovirus infection in children: a brief overview , 2016, European Journal of Pediatrics.
[7] C. Pannecouque,et al. Modification of the length and structure of the linker of N(6)-benzyladenosine modulates its selective antiviral activity against enterovirus 71. , 2016, European journal of medicinal chemistry.
[8] Wienand A. Omta,et al. Screening of a Library of FDA-Approved Drugs Identifies Several Enterovirus Replication Inhibitors That Target Viral Protein 2C , 2016, Antimicrobial Agents and Chemotherapy.
[9] A. Saitoh,et al. Clinical utility of serum samples for human parechovirus type 3 infection in neonates and young infants: The 2014 epidemic in Japan. , 2016, The Journal of infection.
[10] V. Sheppeard,et al. Parechovirus Genotype 3 Outbreak among Infants, New South Wales, Australia, 2013–2014 , 2015, Emerging infectious diseases.
[11] J. Neyts,et al. Broad-range inhibition of enterovirus replication by OSW-1, a natural compound targeting OSBP. , 2015, Antiviral research.
[12] S. Midgley,et al. Human Parechovirus Infection, Denmark , 2014, Emerging infectious diseases.
[13] D. Pajkrt,et al. Successful IVIG Treatment of Human Parechovirus-Associated Dilated Cardiomyopathy in an Infant , 2013, Pediatrics.
[14] D. Pajkrt,et al. Specific cell tropism and neutralization of human parechovirus types 1 and 3: implications for pathogenesis and therapy development. , 2012, The Journal of general virology.
[15] B. Westerhuis,et al. Detection of human enterovirus and human parechovirus (HPeV) genotypes from clinical stool samples: polymerase chain reaction and direct molecular typing, culture characteristics, and serotyping. , 2010, Diagnostic microbiology and infectious disease.
[16] R. Molenkamp,et al. High Prevalence of Human Parechovirus (HPeV) Genotypes in the Amsterdam Region and Identification of Specific HPeV Variants by Direct Genotyping of Stool Samples , 2008, Journal of Clinical Microbiology.
[17] R. Selvarangan,et al. Antifungal azoles itraconazole and posaconazole exhibit potent in vitro antiviral activity against clinical isolates of parechovirus A3 (Picornaviridae). , 2018, Antiviral research.